Anti-CD47 Antibody (B6.H12)
Based on 1 Customer Validation
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma.
For research use only. We do not sell to patients.
- Purity: 96.06%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse IgG1 kappa
Human
CD47
Anti-CD47 Antibody (B6.H12) (10 μg/mL, 2 h) increases macrophage phagocytosis of HepG2 and H3B cells[1].
Anti-CD47 Antibody (B6.H12) (1.1-10 μg/mL, 24-72 h) is not cytotoxic to human hepatocellular carcinoma cells and normal hepatocytes[1].
Anti-CD47 Antibody (B6.H12) (10 μg/mL, 2 h) significantly decreases the proliferation of IOMM-Lee cells[2].
Anti-CD47 Antibody (B6.H12) (10 μg/mL, 24 h) significantly attenuates cell migration and invasion ability in IOMM-Lee cells[2].
Anti-CD47 Antibody (B6.H12) (10 μg/mL, 2 h) induces macrophage-mediated phagocytosis in Meningioma cells[2].
Anti-CD47 Antibody (B6.H12) (100 μg/mL, 5 days) significantly decreases invasion in osteosarcoma cells[3].
Anti-CD47 Antibody (B6.H12) (10 μg/mL, 2 h) increases macrophage phagocytosis of osteosarcoma tumor cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-CD47 Antibody (B6.H12) (100 μg, i.p, daily for 5 weeks) suppresses tumor growth in IOMM-Lee tumor mice models[2].
Anti-CD47 Antibody (B6.H12) (100 μg, i.p, three times weekly) inhibits tumor progression in osteosarcoma mice models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Heterotopic/orthotopic tumor mice models[1]
-
Dosage:400 μg
-
Administration:Intraperitoneally injection, twice a week
-
Result:Inhibited tumor growth.
Showed overall high body masses.
Increased intra-tumor migration of macrophages in Heterotopic tumor models.
-
Animal Model:Nude mice were injected by IOMM-Lee cells[2]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, daily for 5 weeks
-
Result:Inhibited tumor growth and exhibited significantly smaller tumor volume.
-
Animal Model:Osteosarcoma mice models[3]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, three times weekly
-
Result:Showed low mean tibial weight and incidence of spontaneous metastasis.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
in vitro CD47 neutralization; in vivo CD47 neutralization in human tumor xenograft models or humani
-
Flow cytometric analysis of 1X106 Juakat cells with Anti-CD47 Antibody (HY-P990858, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-CD47 Antibody (B6.H12)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Xiao Z, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015 May 1;360(2):302-9. [Content Brief]
[2]. Liu X, et al. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma. Curr Neuropharmacol. 2023;21(10):2159-2173. [Content Brief]
[3]. Xu JF, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget. 2015 Sep 15;6(27):23662-70. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-CD47 Antibody (B6.H12) Related Classifications
HY-P990858 Related Classifications
Powered by Bioz